AroER tri-screen™ is a novel functional assay to estimate both estrogenic and estrogen precursor activity of chemicals or biological specimens

[1]  E. Simpson,et al.  Transcriptional control of local estrogen formation by aromatase in the breast , 2015, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  Menghang Xia,et al.  AroER tri-screen is a biologically relevant assay for endocrine disrupting chemicals modulating the activity of aromatase and/or the estrogen receptor. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  Jian-Min Yuan,et al.  Serum estrogen receptor bioactivity and breast cancer risk among postmenopausal women. , 2014, Endocrine-related cancer.

[4]  K. Schramm,et al.  Coexposure to phytoestrogens and bisphenol a mimics estrogenic effects in an additive manner. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  P. Khanna,et al.  Acute perioperative pain in neonates: An evidence-based review of neurophysiology and management. , 2014, Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists.

[6]  J. Gustafsson,et al.  Insight into the mechanisms of action of estrogen receptor β in the breast, prostate, colon, and CNS. , 2013, Journal of molecular endocrinology.

[7]  Weida Tong,et al.  EADB: an estrogenic activity database for assessing potential endocrine activity. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  F. Berrino,et al.  Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. , 2013, The Lancet. Oncology.

[9]  Ruili Huang,et al.  Using in Vitro High Throughput Screening Assays to Identify Potential Endocrine-Disrupting Chemicals , 2012, Environmental health perspectives.

[10]  Jian-Min Yuan,et al.  Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women. , 2012, Bone.

[11]  I. Jacobs,et al.  Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women , 2011, Endocrine-related cancer.

[12]  C. Casals-Casas,et al.  Endocrine disruptors: from endocrine to metabolic disruption. , 2011, Annual review of physiology.

[13]  R. Hoover,et al.  A new approach to measuring estrogen exposure and metabolism in epidemiologic studies , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[14]  Peter C Austin,et al.  Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study , 2010, BMJ : British Medical Journal.

[15]  S Apostolidou,et al.  Serum oestrogen receptor α and β bioactivity are independently associated with breast cancer: a proof of principle study , 2009, British Journal of Cancer.

[16]  L. Giudice,et al.  Endocrine-disrupting chemicals: an Endocrine Society scientific statement. , 2009, Endocrine reviews.

[17]  Tanja Krüger,et al.  Xenobiotic activity in serum and sperm chromatin integrity in European and inuit populations , 2008, Molecular reproduction and development.

[18]  Y. Kanno,et al.  Effects of Endocrine Disrupting Substance on Estrogen Receptor Gene Transcription in Dialysis Patients , 2007, Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy.

[19]  Jun Li,et al.  Ultrasensitive cell-based bioassay for the measurement of global estrogenic activity of flavonoid mixtures revealing additive, restrictive, and enhanced actions in binary and higher order combinations. , 2007, Assay and drug development technologies.

[20]  E. Bonefeld‐Jørgensen,et al.  SPE-HPLC purification of endocrine-disrupting compounds from human serum for assessment of xenoestrogenic activity , 2006, Analytical and bioanalytical chemistry.

[21]  J. Chang-Claude,et al.  Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. , 2005, Endocrine-related cancer.

[22]  M. Hurtt,et al.  Relationship between cyclooxygenase 1 and 2 selective inhibitors and fetal development when administered to rats and rabbits during the sensitive periods for heart development and midline closure. , 2003, Birth defects research. Part B, Developmental and reproductive toxicology.

[23]  T. Key,et al.  Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. , 2002, Journal of the National Cancer Institute.

[24]  P. Adriaensens,et al.  17α-ethyl-5β-estrane-3α,17β-diol, a biological marker for the abuse of norethandrolone and ethylestrenol in slaughter cattle , 1999 .

[25]  P. Thomas,et al.  Characterization of two nuclear androgen receptors in Atlantic croaker: comparison of their biochemical properties and binding specificities. , 1999, Endocrinology.

[26]  F. Piferrer,et al.  Effects of natural, synthetic, aromatizable, and nonaromatizable androgens in inducing male sex differentiation in genotypic female chinook salmon (Oncorhynchus tshawytscha). , 1993, General and comparative endocrinology.

[27]  Y. Touitou,et al.  Evidence for a new biologic pathway of androstenedione synthesis from 11-deoxycortisol , 1991, Steroids.

[28]  A. Schuurs,et al.  Effects of tibolone, lynestrenol, ethylestrenol, and desogestrel on autoimmune disorders in NZB/W mice. , 1986, Clinical immunology and immunopathology.

[29]  A. Calin.  DRUG TREATMENT OF RHEUMATOID ARTHRITIS , 1975, The Lancet.

[30]  J. Calnan,et al.  Ethyloestrenol and postoperative venous thrombosis. , 1973, Lancet.

[31]  P. Adriaensens,et al.  17alpha-ethyl-5beta-estrane-3alpha, 17beta-diol, a biological marker for the abuse of norethandrolone and ethylestrenol in slaughter cattle. , 1999, Journal of chromatography. B, Biomedical sciences and applications.